文献速递药物相互作用抗栓抗凝管理特殊人群用药

HIV-1感染患者的心房颤动:系统综述及其对抗凝与抗心律失常治疗的启示

Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy.
PubMed 文献 · Br J Clin Pharmacol · 2019-01-11

该系统综述检索PubMed与Cochrane系统综述数据库并筛查参考文献,汇总HIV-1感染与房颤/房扑关联的临床研究,同时总结抗逆转录病毒药与抗血栓及抗心律失常药的相互作用。结果显示HIV-1患者房颤/房扑患病率为2.0%–5.13%,发病率为3.6/1000人年,低CD4+计数与高病毒载量为预测因素,并提示需关注药物相互作用。

要点

  • HIV-1患者房颤/房扑患病率2.0%–5.13%,发病率3.6/1000人年。
  • 低CD4+计数(<200–250 cells ml-1)与高病毒载量为房颤/房扑预测因素。
  • 达比加群在抗凝药中相互作用谱最有利,β受体阻滞剂与地尔硫䓬抗心律失常相互作用较少。

核心结论

  • 现有少数研究提示HIV-1感染患者中房颤/房扑患病率不可忽视。
  • 需认识抗凝与抗心律失常药物的潜在相互作用,以优化该人群管理。

研究设计与样本

  • 系统综述,检索PubMed与Cochrane系统综述数据库并筛查参考文献。
  • 纳入报告HIV-1感染与房颤/房扑关联的临床研究,并总结抗逆转录病毒药与抗血栓及抗心律失常药的相互作用。

主要发现

  • HIV-1患者房颤/房扑患病率为2.0%–5.13%,发病率为3.6/1000人年。
  • 低CD4+计数(<200–250 cells ml-1)与高病毒载量为房颤/房扑的预测因素。

关键数值与推荐

  • 核苷类逆转录酶抑制剂、整合酶抑制剂与maraviroc与口服抗凝药相互作用最少。
  • 抗凝药中达比加群相互作用谱最有利。
  • 多数抗心律失常药与蛋白酶抑制剂存在相互作用,β受体阻滞剂与地尔硫䓬相互作用较少。

临床怎么用

  • HIV-1感染合并房颤/房扑患者选抗凝药时可优先考虑相互作用较少的方案。
  • 选用抗心律失常药时需评估与蛋白酶抑制剂的相互作用,β受体阻滞剂与地尔硫䓬可作为相互作用较少的选项。

局限性

  • 可用的相关研究较少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The prevalence and incidence of atrial fibrillation/flutter (AF/AFL) in patients with human immunodeficiency virus type-1 (HIV-1) infection have been poorly investigated. We performed a systematic review using PubMed and Cochrane Database of Systematic Reviews, and screening of references, searching for clinical studies reporting on the association between HIV-1 infection and AF/AFL. We also summarized the main interactions of antiretroviral agents with antithrombotic and antiarrhythmic drugs. We found a prevalence of AF/AFL ranging from 2.0% to 5.13% in patients with HIV-1, with an incidence rate of 3.6/1000 person-years. Low CD4+ count (<200-250 cells ml-1 ) and high viral load were predictors of AF/AFL. Regarding drugs interactions, nucleoside reverse transcriptase inhibitors, integrase inhibitor and maraviroc have the lowest interactions with oral anticoagulants. Among anticoagulants, dabigatran presents the most favourable profile. Most of antiarrhythmic drugs interact with protease inhibitors, with beta blockers and diltiazem having fewer interactions. The few studies available suggest a non-negligible prevalence of AF/AFL in patients with HIV-1 infection. Awareness of potential interactions with anticoagulation and antiarrhythmic drugs is needed to offer optimal management in this population.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Pastori D, Mezzaroma I, Pignatelli P, et al. Atrial fibrillation and human immunodeficiency virus type-1 infection: a systematic review. Implications for anticoagulant and antiarrhythmic therapy. Br J Clin Pharmacol. 2019. PMID: 30575989. doi:10.1111/bcp.13837

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。